Skip to main content
Top
Published in: Respiratory Research 1/2022

Open Access 01-12-2022 | Pulmonary Hypertension | Research

Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD

Authors: Teresa Sassmann, Philipp Douschan, Vasile Foris, Natascha Tröster, Katarina Zeder, Luka Brcic, Adrienn Tornyos, Gerhard Bachmaier, Michael Fuchsjäger, Horst Olschewski, Gabor Kovacs

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background

Pulmonary hypertension (PH) is a frequent complication in COPD and it is associated with decreased exercise capacity and poor prognosis. We hypothesized that even in COPD patients without significant PH at rest, abnormal pulmonary hemodynamics during exercise affect exercise capacity.

Methods

Consecutive COPD patients with clinically indicated right heart catheterization and resting mean pulmonary arterial pressure (mPAP) < 25 mmHg and age- and sex-matched controls with the same limits of pulmonary hemodynamics but no chronic lung disease who underwent clinical work-up including invasive hemodynamic assessment during exercise, were retrospectively analyzed. Chi-square tests were used to evaluate differences between groups for categorical data and Fisher’s exact test or Mann–Whitney-U-tests for continuous variables. Associations were analyzed with Spearman rank correlation tests.

Results

We included n = 26 COPD patients (female/male: 16/10, 66 ± 11 yr, FEV1: 56 ± 25%predicted) and n = 26 matched controls (FEV1: 96 ± 22%predicted). At rest, COPD patients presented with slightly increased mPAP (21 (18–23) vs. 17 (14–20) mmHg, p = 0.022), and pulmonary vascular resistance (PVR) [2.5 (1.9–3.0) vs. 1.9 (1.5–2.4) WU, p = 0.020] as compared to controls. During exercise, COPD patients reached significantly higher mPAP [47 (40–52) vs. 38 (32–44) mmHg, p = 0.015] and PVR [3.1 (2.2–3.7) vs. 1.7 (1.1–2.9) WU, p = 0.028] values despite lower peak exercise level [50 (50–75) vs. 100 (75–125) Watt, p = 0.002]. The mPAP/cardiac output slope was increased in COPD vs. controls [6.9 (5.5–10.9) vs. 3.7 (2.4–7.4) mmHg/L/min, p = 0.007] and negatively correlated with both peak oxygen uptake (r = − 0.46, p = 0.007) and 6-min walk distance (r = − 0.46, p = 0.001).

Conclusion

Even in the absence of significant PH at rest, COPD patients reveal characteristic abnormalities in pulmonary hemodynamics during exercise, which may represent an important exercise-limiting factor.
Appendix
Available only for authorised users
Literature
1.
go back to reference Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203:24–36. https://doi.org/10.1164/rccm.202009-3533SO.CrossRef Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ, et al. Global initiative for the diagnosis, management, and prevention of chronic obstructive lung disease. The 2020 GOLD science committee report on COVID-19 and chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2021;203:24–36. https://​doi.​org/​10.​1164/​rccm.​202009-3533SO.CrossRef
14.
go back to reference Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75. https://doi.org/10.1183/13993003.01032-2015.CrossRef Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903–75. https://​doi.​org/​10.​1183/​13993003.​01032-2015.CrossRef
24.
38.
Metadata
Title
Abnormal pulmonary hemodynamics during exercise is associated with exercise capacity in COPD
Authors
Teresa Sassmann
Philipp Douschan
Vasile Foris
Natascha Tröster
Katarina Zeder
Luka Brcic
Adrienn Tornyos
Gerhard Bachmaier
Michael Fuchsjäger
Horst Olschewski
Gabor Kovacs
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-02238-9

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.